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microRNA-10b enhances pancreatic cancer cell invasion
by suppressing TIP30 expression and promoting EGF
and TGF-b actions
H Ouyang, J Gore, S Deitz and M Korc
Increased microRNA-10b (miR-10b) expression in the cancer cells in pancreatic ductal adenocarcinoma (PDAC) is a marker of
disease aggressiveness. In the present study, we determined that plasma miR-10b levels are signiﬁcantly increased in PDAC patients
by comparison with normal controls. By gene proﬁling, we identiﬁed potential targets downregulated by miR-10b, including
Tat-interacting protein 30 (TIP30). Immunoblotting and luciferase reporter assays conﬁrmed that TIP30 was a direct miR-10b target.
Downregulation of TIP30 by miR-10b or siRNA-mediated silencing of TIP30 enhanced epidermal growth factor (EGF)-dependent
invasion. The actions of miR-10b were abrogated by expressing a modiﬁed TIP30 cDNA resistant to miR-10b. EGF-induced EGF
receptor (EGFR) tyrosine phosphorylation and extracellular signal–regulated kinase phosphorylation were enhanced by miR-10b,
and these effects were mimicked by TIP30 silencing. The actions of EGF in the presence of miR-10b were blocked by EGFR kinase
inhibition with erlotinib and by dual inhibition of PI3K (phosphatidylinositol 30-kinase) and MEK. Moreover, miR-10b, EGF and
transforming growth factor-beta (TGF-b) combined to markedly increase cell invasion, and this effect was blocked by the
combination of erlotinib and SB505124, a type I TGF-b receptor inhibitor. miR-10b also enhanced the stimulatory effects of EGF and
TGF-b on cell migration and epithelial–mesenchymal transition (EMT) and decreased the expression of RAP2A, EPHB2, KLF4 and
NF1. Moreover, miR-10b overexpression accelerated pancreatic cancer cell (PCC) proliferation and tumor growth in an orthotopic
model. Thus, plasma miR-10b levels may serve as a diagnostic marker in PDAC, whereas intra-tumoral miR-10b promotes PCC
proliferation and invasion by suppressing TIP30, which enhances EGFR signaling, facilitates EGF–TGF-b cross-talk and enhances the
expression of EMT-promoting genes, whereas decreasing the expression of several metastasis-suppressing genes. Therefore,
therapeutic targeting of miR-10b in PDAC may interrupt growth-promoting deleterious EGF–TGF-b interactions and antagonize the
metastatic process at various levels.
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INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading
cause of cancer-related deaths in the United States with a median
survival of 6 months and a 5-year survival rate of 6%.1 As there
are no effective modalities for early detection, most PDAC patients
present with locally invasive and/or metastatic disease and are not
candidates for resection.2 Histologically, PDAC is characterized
by regions of acinar-to-ductal metaplasia, pancreatic intra-
epithelial neoplasia, cancer cells forming ductal-like structures,
inﬂammatory inﬁltrates and an extensive desmoplastic reaction
that interferes with effective drug delivery into the pancreatic
tumor mass.3–5 At the molecular level, there is a high frequency
of major driver mutations in key regulatory genes, including
KRAS, TP53, CDKN2A and SMAD4, an abundance of low-
frequency driver mutations and aberrant activation of multiple
signaling pathways as a consequence of the overexpression
of multiple tyrosine kinase receptors, such as the epidermal
growth factor (EGF) receptor (EGFR) and its ligands, and
excessive production of transforming growth factor-beta (TGF-b)
isoforms.6,7
EGFR homodimerization and heterodimerization with other
EGFR family members leads to enhanced tyrosine kinase activity
of the receptor complexes and activation of multiple signaling
pathways, such as mitogen-activated protein kinase (MAPK), p38
MAPK, phosphatidylinositol 30-kinase (PI3K), Src, Crk and Nck.8,9 By
contrast, TGF-b activates serine-threonine receptor kinases, which
act through canonical, Smad-dependent signaling as well as non-
canonical, Smad-independent signaling, and generally exert
paracrine effects on the tumor microenvironment in PDAC.10–12
However, TGF-b can also directly enhance the invasion of
pancreatic cancer cells (PCCs) and stimulate PCC proliferation,13
indicating that EGF–TGF-b interactions are important with respect
to cell-autonomous effects in PDAC.
MicroRNAs (miRs) constitute a class of 18–25 nucleotide
non-coding RNAs that target speciﬁc mRNA moieties for transla-
tional repression or degradation.14 Expression of miRs is often
deregulated in cancer, and miRs participate in the regulation of
many important biological processes, including cell survival,
proliferation, migration, invasion and metastasis.15,16 Several
miRs are overexpressed in PDAC, including miR-10b, miR-21,
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miR-196a, miR-203, miR-155, miR-210 and miR-221.17–22 Moreover,
miR-10b is one of the most frequently upregulated miRs in
PDAC,18,22 and high miR-10b levels in the cancer cells in PDAC are
associated with decreased therapeutic response to multimodality
neoadjuvant therapy, shorter time to metastasis, decreased overall
patient survival and increased PCC invasiveness.22–24 However, it is
not clear how miR-10b promotes PCC invasion in PDAC.
In the present study, we determined that miR-10b enhanced EGF-
induced invasion, EGFR phosphorylation and extracellular signal–
regulated kinase 1 (ERK1)/2 activation in PCCs, whereas attenuating
EGFR degradation and that these effects were due to miR-10b-
induced downregulation of Tat-interacting protein 30 (TIP30).
Moreover, the combination of high levels of miR-10b, EGF and
TGF-bmarkedly enhanced cell invasion and altered gene expression
in a manner that was consistent with epithelial–mesenchymal
transition (EMT) induction. Given that miR-10b, EGFR and TGF-b are
often overexpressed in PDAC,22–26 these observations suggest that
targeting miR-10b may serve to suppress metastases and to
interrupt deleterious EGF–TGF-b interactions in PDAC.
RESULTS
miR-10b is expressed at high levels in the cancer cells in PDAC,18,22
and several studies have implicated miR-10b in cancer
metastasis.27,28 To conﬁrm that miR-10b expression is increased
in PDAC, we took advantage of the known resistance of miRs to
degradation in the circulation and assayed miR-10b levels in the
plasma of 20 normal controls, 5 patients with chronic pancreatitis
and 17 PDAC patients. miR-10b levels were increased 575-fold in
PDAC patients by comparison with the corresponding levels in
either normal controls (Po0.001) or patients with chronic
pancreatitis (Figure 1a; Po0.001).
Given that the metastatic process is preceded by invasion, we
sought to identify invasion-associated miR-10b targets that could
lead to enhanced metastasis in PDAC. Accordingly, microarray
studies were conducted using RNA from PANC-1 cells transfected
with a miR-10b precursor. Fifty-ﬁve genes were downregulated by at
least 40% upon miR-10b overexpression (Supplementary Table S1),
and three of these genes (RAP2A, EPHB2 and TIP30) affect pathways
that have the potential to suppress cancer cell invasion. Quantitative
reverse transcription PCR (qRT–PCR) conﬁrmed that the mRNA levels
of all three genes were signiﬁcantly decreased in PANC-1 cells
expressing high levels of miR-10b compared with respective controls
(Figure 1b). In silico analysis with miRanda, PicTar and TargetScan
computational tools for miRNA target prediction conﬁrmed that
TIP30, RAP2A and EPHB2 were potential miR-10b targets.
TIP30, also known as HIV-1 Tat interactive protein 2 (HTATIP2) or
CC3, was of particular interest, because it suppresses metastases in
Figure 1. miR-10b targets. (a) Plasma miR-10b levels. Compared with plasma from normal controls (n¼ 20; closed circles) and chronic
pancreatitis patients (CP; n¼ 5; gray circles), miR-10b levels are significantly elevated (Po.001) in the plasma of PDAC patients (n¼ 18; open
circles). Horizontal bars denote mean expression levels. (b) Gene expression. qRT–PCR of indicated mRNAs in PANC-1 cells transfected with
control (solid bars) or precursor miR-10b (open bars) confirmed the array results. (c) TIP30 levels. qRT–PCR was used to determine TIP30 mRNA
levels in PANC-1 cells transfected with control (solid bars) or precursor miR-10b (open bars) for the indicated times. (d) TIP30 immunoblotting.
A highly specific anti-TIP30 antibody was used in immunoblotting analysis, revealing a marked decrease in TIP30 protein levels in the
presence of miR-10b by comparison with control. (e) Luciferase reporter constructs. The reporter constructs encoded a wild-type (WT) TIP30
30UTR or a mutant (M) TIP30 30UTR in which the binding site was replaced by the indicated nucleotides. (f ) Luciferase readout. PANC-1 cells
were transfected with control (solid bars) or precursor miR-10b (open bars) for 20 h together with WT or M TIP30 30UTR luciferase constructs.
Data in panels b, c, and f, are the means±s.e.m. from three experiments, analyzed by two-way ANOVA followed by Bonferroni’s adjustment.
*Po0.01 and **Po0.001 compared with its respective controls.
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lung, breast and hepatocellular cancers29–31 and regulates
EGF-induced EGFR endocytosis.32 Given the important role of
EGFR in PDAC,25,33 we sought to conﬁrm that miR-10b
downregulates TIP30 mRNA and protein levels. Accordingly, qRT–
PCR and immunoblotting were conducted using RNA and protein
extracted from miR-10b-overexpressing PANC-1 cells. Increased
miR-10b expression led to decreased TIP30 mRNA (Figure 1c) and
protein (Figure 1d) levels at 24, 48 and 72h post transfection. A
similar decrease in TIP30 protein levels was seen in ASPC-1, COLO-
357 and T3M4 human PCCs following transfection with miR-10b
precursor (Supplementary Figure S1a), indicating that this down-
regulation was not unique to PANC-1 cells. Moreover, transfection
with the miR-10a precursor, which shares the same sequence with
miR-10b except for a difference of one nucleotide in the non-seed
region,34 resulted in variable but reproducible decreases in TIP30
levels in all the four PCCs (Supplementary Figure S1a).
To conﬁrm that TIP30 is a direct target of miR-10b, we used a
TIP30 30 untranslated region (UTR) luciferase construct, and a
mutant construct in which 6 nucleotides in the potential binding
site were replaced (Figure 1e). Co-transfection of PANC-1 cells with
the TIP30 30UTR construct and miR-10b precursor caused a 50%
decrease in luciferase activity compared with the negative control,
and this suppression of TIP30 expression was completely reversed
by the six-nucleotide substitution in the core binding site
(Figure 1f).
EGF and TGF-b promote PCC invasion.12 To determine whether
miR-10b enhances human PCC invasion and whether it modulates
the actions of either EGF or TGF-b, miR-10b precursor was
transfected into two human PCCs. In PANC-1 and COLO-357 cells,
EGF (1 nM) or TGF-b1 (0.5 nM) enhanced invasion, and their
combined action was greater than that of either growth factor
alone (Figures 2a and b). Overexpression of miR-10b increased
invasion in PANC-1 cells and enhanced EGF-mediated invasion in
both PCCs and TGF-b1-mediated invasion in COLO-357 cells.
Moreover, the combination of both growth factors exerted a
signiﬁcantly (Po0.005) greater stimulatory effect on invasion in
cells with high miR-10b levels (Figures 2a and b), which is
potentially important clinically given that miR-10b, EGFR and TGF-
b are all overexpressed in PDAC.22–26
To determine whether TIP30 knockdown mimics miR-10b
actions on PCC invasion, PANC-1 cells were transfected with two
siRNAs targeting TIP30. TIP30 silencing by either siRNA reduced
TIP30 levels (Supplementary Figure S1b) and increased EGF-
stimulated invasion (Figure 2c), indicating that TIP30 is a negative
regulator of PCC invasion. To conﬁrm that TIP30 downregulation
was essential for miR-10b-induced stimulation of cell invasion, we
used the pCMV-SPORT6-TIP30 vector, which encodes a TIP30
cDNA that is not regulated by miR-10b due to a mutated 30UTR
binding site. Experiments were carried out in the presence of 1 nM
EGF and in the absence or presence of transfected miR-10b using
cells expressing empty vector or the pCMV-SPORT6-TIP30 vector.
This experimental design allowed for the speciﬁc evaluation of the
consequence of expressing a TIP30 that was resistant to miR-10b
downregulation. When pCMV-SPORT6-TIP30 was transfected into
PANC-1 cells, the stimulatory effect of miR-10b overexpression on
EGF-induced invasion was completely abrogated (Figure 2d). Thus,
TIP30 is a functional target of miR-10b whose downregulation
promotes EGF-induced invasion.
Invasion is often associated with enhanced cancer cell motility.
Therefore, we next sought to determine whether miR-10b
modulated PCC migration. In COLO-357 cells, miR-10b, EGF
(1 nM), TGF-b1 (0.5 nM) or the combination of EGF and TGF-b1
also increased cell migration (Figure 2e). Moreover, in the
presence of miR-10b, the combined effect of EGF and TGF-b1
on migration was signiﬁcantly greater than with either growth
factor alone (Figure 2e). By contrast, in PANC-1 cells EGF enhanced
migration only following miR-10b transfection, whereas TGF-b1
and the combination of EGF and TGF-b1 signiﬁcantly increased
migration in control cells, and these effects were enhanced in the
presence of miR-10b (Figure 2f).
Speciﬁc inhibitors were used next to conﬁrm that EGF and TGF-
b acted through their respective receptors with respect to their
individual and combined stimulatory effects on invasion in the
presence of miR-10b. The EGFR inhibitor erlotinib (2 mM) com-
pletely blocked EGF-induced invasion in the presence of miR-10b
in both the COLO-357 and PANC-1 cells (Figures 3a and b).
Although the PI3K inhibitor LY294002 (10 mM) and the MEK
inhibitor UO126 (1 mM) partially blocked this effect, the combina-
tion of LY294002 and UO126 were as effective as erlotinib in
suppressing EGF-mediated invasion (Figures 3a and b). Moreover,
miR-10b’s effects on combined EGF–TGF-b1 actions on invasion
were markedly attenuated by EGFR kinase inhibition with erlotinib
and TbRI kinase inhibition with SB505124 and were abrogated by
their combined actions (Figures 3c and d), indicating that EGF and
TGF-b1 act through their respective receptors to cross-talk and
enhance invasion.
TIP30 is a crucial component of the complex that regulates
endocytotic trafﬁcking of EGFR in breast and liver cancer cells
and may act to prolong downstream signaling.31,32 We there-
fore sought to determine whether miR-10b modulates EGFR
expression and signaling in PANC-1 cells. In control-transfected
cells, EGF caused a gradual decrease in EGFR protein levels, and
this effect was attenuated in miR-10b-overexpressing cells
(Figure 3e) but was not associated with any alteration in EGFR
mRNA levels (not shown). EGF also rapidly increased EGFR (Tyr
1148) and ERK1/2 phosphorylation (Thr-202/Tyr-204), and both of
these effects were enhanced by miR-10b (Figure 3e). By contrast,
EGF-induced AKT phosphorylation (Ser 473) and p38 MAPK
phosphorylation (Thr-180/Tyr-182) were not altered by miR-10b
(Figure 3e).
To assess whether downregulation of TIP30 alone is sufﬁcient to
modulate EGFR signaling in PCCs, TIP30 levels were suppressed
with siRNA 6 (Supplementary Figure S1b). TIP30 knockdown
attenuated EGF-induced EGFR downregulation and enhanced
EGFR and ERK1/2 phosphorylation without altering p38 MAPK
phosphorylation (Figure 3f). In contrast to the actions of miR-10b,
siRNA targeting of TIP30 enhanced EGF-induced AKT phos-
phorylation (Figure 3f), suggesting that TIP30 may suppress
pro-survival signals independently of its actions on EGFR
downregulation.
Cancer cell invasion is often associated with enhanced EMT, and
TGF-b1 induces EMT in PCCs.35 Accordingly, we next sought to
determine whether miR-10b modulated the effects of TGF-b and
EGF on the expression of EMT-associated genes (Figure 4). In both
the COLO-357 and PANC-1 cells, miR-10b signiﬁcantly decreased
E-cadherin levels, and this effect was most pronounced in the
presence of the combination of TGF-b1 and EGF (Figure 4a). In
both the cell lines, EGF plus TGF-b1 increased N-cadherin and
vimentin expression but only in the presence of high miR-10b
levels (Figures 4b and c). Moreover, in the presence of miR-10b,
N-cadherin expression was increased by TGF-b1 alone in COLO-
357 cells and by EGF alone in PANC-1 cells, where EGF plus TGF-b1
also increased N-cadherin in the absence of added miR-10b
(Figure 4b). Snail and Zeb1 expression was increased in COLO-357
cells in response to either or both the growth factors in the
presence of miR-10b, as well as in the presence of both the
growth factors without added miR-10b (Figures 4d and e). By
contrast, PANC-1 cells exhibited increased Snail levels only in
response to both the growth factors, and this effect was increased
slightly by miR-10b (Figure 4d). Increases in Zeb1 expression in
PANC-1 cells paralleled those observed in COLO-357 cells, except
that TGF-b1 was effective even in the absence of added miR-10b
(Figure 4e).
We next examined the effects of miR-10b on the expression of
several known miR-10b target genes,27,36–40 HOXD10, TIAM1, KLF4,
SDC1 and NF1 in AsPC-1, COLO-357 and PANC-1 cells. By qRT–PCR,
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KLF4, SDC1 and NF1 expression was decreased by miR-10b in all
the three cell lines (Figure 5a), whereas NF2 expression was not
altered (Figure 5a). Moreover, miR-10b did not alter the expression
of either HOXD10 or TIAM1 (not shown).
We next sought to determine whether TIP30 was expressed in
human PDAC samples using the same highly speciﬁc antibody
that was used in the immunoblotting experiments. TIP30 was
readily visible in the cytoplasm of many cancer cells but not in the
adjoining stroma. Moreover, high TIP30 expression was principally
seen in well to moderately differentiated PDAC (Figure 5b),
whereas low TIP30 expression was seen in poorly differentiated
PDAC (Figure 5c).
To validate the contribution of miR-10b to PDAC biological
aggressiveness, we carried out an in vivo study in an orthotopic
model using athymic mice (Figure 6) and T3M4 cells engineered to
stably overexpress miR-10b. T3M4 cells were used for these
studies as they express high EGFR levels41 and low miR-10b levels
(not shown). Both control and miR-10b-overexpressing T3M4 cells
formed intra-pancreatic tumors in all mice, but the presence of
high levels of miR-10b resulted in faster growing and larger
tumors (Figures 6a and b). Although the two tumor groups were
similar histologically, miR-10b-overexpressing tumors exhibited
many Ki67-positive cells reﬂecting the presence of a large number
of cells in late G1, S, G2 or M phase (Figure 6c). Moreover, there
was a marked increase in the number of phospho-histone
H3-positive cancer cells that are undergoing mitosis in the
miR-10b-overexpressing tumors by comparison with control
tumors (Figure 6c). Thus, miR-10b exerts multiple deleterious
Figure 2. Effects of miR-10b, EGF and TGF-b1 on invasion and migration, and consequences of TIP30 downregulation on invasion. (a, b) Effects
of miR-10b, EGF and TGF-b1 on invasion. COLO-357 (a) and PANC-1 (b) cells were transfected with control (solid bars) or miR-10b (open bars)
precursors and plated (5 104 cells/well) in a Matrigel-coated Boyden chamber. Invasion was determined after incubating cells for 20 h in the
absence (serum free: SF) or presence of EGF (E, 1 nM), TGF-b1 (T, 0.5 nM) or both EGF and TGF-b1 (Eþ T). Cells that had invaded across the
membrane were stained and counted. (c) TIP30 silencing. PANC-1 cells were transfected with scrambled control or two siRNAs (5 and 6)
targeting TIP30. Cells (5 104 cells per well) were then plated for Matrigel invasion assays in the absence or presence of EGF (1 nM) for 20 h.
(d) Effects of mutant TIP30 on miR-10b-enhanced invasion. PANC-1 cells were transfected for 48 h with control or precursor miR-10b in
combination with either empty pCMV-SPORT6 (Empty) or pCMV-SPORT6-TIP30 carrying a mutated TIP30 cDNA(TIP30 Mutant) that is resistant
to miR-10b-induced downregulation. Effects on invasion by 1nM EGF were then determined. Data in each panel are the means±s.e.m. from
three experiments and were analyzed by two-way ANOVA followed by Bonferroni’s adjustment. *Po0.05, **Po0.01 and ***Po0.001
compared with respective controls; #Po0.05, compared with corresponding control SF; wPo0.01 compared with EGF alone and zPo0.01
compared with TGF-b1 alone in cells transfected with miR-10b precursor; wPo0.05 compared with empty pCMV-SPORT6, and *Po0.05
compared with pCMV-SPORT6-TIP30 in miR-10b-transfected group. (e, f ) Migration assays. COLO-357 (e) and PANC-1 (f ) cells were transfected
with control (solid bars) or miR-10b precursors (open bars). Cells (5 104 cells/well) were then used in a wound-healing assay and incubated
for 20 h in the absence (SF) or presence of EGF (E, 1 nM), TGF-b1 (T, 0.5 nM) or both EGF and TGF-b1 (Eþ T). The wound area was measured at 0
and 20h using ImageJ software (NIH, Bethedsa, MD, USA). Migration was calculated as the percentage of change in wound area. Two-way
ANOVA was performed followed by Bonferroni’s adjustment. **Po0.01 and ***Po0.001 compared with respective controls; #Po0.001
compared with control SF; wPo0.05 and wwwPo0.001 compared with EGF alone in cells transduced with miR-10b; zPo0.05 and zzzPo0.001
compared with TGF-b1 alone in cells transduced with miR-10b.
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actions in PCCs, which include upregulation of EGFR signaling,
downregulation of NF-1 and decreased expression of metastasis-
suppressing genes, thereby contributing to increased PCC
proliferation and invasion (Figure 6d).
DISCUSSION
miR-10b was initially reported as a metastasis promoter in breast
cancer27 and subsequently implicated in enhancing metastasis in
cancers of the esophagus,37 colon,42 liver43 and pancreas24 and
invasion in glioblastoma.38 In breast cancer, miR-10b downregulates
HOXD10 leading to the increased expression of the metastasis-
promoting RhoC.27 Moreover, in a syngeneic orthotopic mouse
model of breast cancer, miR-10b antagomirs signiﬁcantly
attenuated the frequency of metastases to the lungs.28
In the present study, we determined that plasma miR-10b levels
are markedly increased in PDAC patients by comparison with
either normal subjects or patients with chronic pancreatitis,
suggesting that assaying for miR-10b could potentially be a useful
diagnostic biomarker. Moreover, miR-10b overexpression in PCCs
enhanced EGF-stimulated invasion. By gene proﬁling, immuno-
blotting and luciferase reporter assays, TIP30 was identiﬁed as a
target directly downregulated by miR-10b overexpression. Four
lines of evidence suggested that miR-10b promoted EGF-
mediated invasion by downregulating TIP30 and enhancing EGFR
signaling. First, the expression of a TIP30 cDNA resistant to
Figure 3. Effects of signaling inhibitors on invasion and effects of miR-10b on signaling. (a, b) Effects of EGFR inhibitor erlotinib and
downstream inhibitors on invasion. COLO-357 (a) and PANC-1 (b) cells were transfected with miR-10b precursor were incubated for 20 h
without EGF (SF) or with EGF (1 nM) in the absence (D: DMSO) or presence of 2 mM erlotinib (E), 10 mM LY294002 (LY: PI3K inhibitor) or 1 mM
UO126 (U: MEK inhibitor). (c, d) Effects of erlotinib and TbRI inhibition with SB505124 on invasion. COLO-357 (c) and PANC-1 (d) cells
transfected with miR-10b precursor were incubated for 20 h without growth factor ( ) or with 1 nM EGF and 0.5 nM TGF-b1 (þ ) in the absence
(D: DMSO) or presence of erlotinib (E, 2mM) or SB505124 (SB, 10 mM), and effects on invasion were determined. Data in all panels are the
means±s.e.m. from three experiments and were analyzed by ANOVA followed by Bonferroni’s adjustment. In panels (a) and (b), *Po0.05,
**Po0.01 and ***Po0.001 compared with EGF alone; in panels (c) and (d) ***Po0.001 compared with EGF and TGF-b1 combination
and wPo0.05 compared with corresponding serum free (SF) values. (e, f ) Effects of miR-10b overexpression and TIP30 knockdown on EGFR
signaling. (e) PANC-1 cells transfected with control or miR-10b precursor were incubated in the absence of presence of 1 nM EGF for
the indicated times. Immunoblotting for the indicated proteins was then carried out. ERK2 was used to assess loading of lanes. (f ) Effects of
TIP30 silencing on EGFR signaling. PANC-1 cells transfected with control siRNA or siRNA targeting TIP30 were incubated in the absence
or presence of 1 nM EGF for the indicated times. Immunoblotting for the indicated proteins was then carried out, ERK2 serving to assess
loading of lanes.
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silencing by miR-10b abrogated miR-10b actions on invasion.
Second, siRNA-mediated silencing of TIP30 resulted in increased
EGF-mediated invasiveness. Third, both high miR-10b levels and
TIP30 knockdown enhanced EGF-induced EGFR tyrosine phos-
phorylation and ERK phosphorylation, whereas attenuating EGFR
downregulation. Fourth, EGF-mediated invasion in the presence
of high miR-10b levels was blocked by erlotinib and by the
combined actions of the PI3K inhibitor LY294002 and the MEK
inhibitor UO126, two key pathways downstream of EGFR
activation.
PCCs and PDACs express high levels of EGFR, a known
mediator of mitogenic signals in general and a promoter of PCC
Figure 4. Effects of miR-10b on expression of genes implicated in EMT. (a, e) qRT–PCR. Control (solid bars) or miR-10b precursor (open bars)
transfected COLO-357 and PANC-1 cells were incubated in the absence (serum free: SF) or presence of EGF (E, 1 nM), TGF-b1 (T, 0.5 nM) or
both EGF and TGF-b1 (Eþ T) for 24 h and then harvested for RNA extraction and qRT–PCR for E-cadherin (a), N-cadherin (b), Vimentin (c),
Snail (d) and Zeb1 (e). Data are the means±s.e.m. from four experiments. Two-way ANOVA was performed followed by Bonferroni’s
adjustment. *Po0.05, **Po0.01 and ***Po0.001 compared with respective control transfected cells; #Po0.05, ##Po0.01, and ###Po0.001
compared with respective cells in SF condition.
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invasion and metastasis that is essential for PDAC initiation
and progression.44–46 PDACs also express high levels of human
EGFR 2 (HER2) and HER3, which heterodimerize with EGFR
thereby diversifying and amplifying signaling cascades.47,48
Moreover, PDACs express high levels of TGF-bs, 14-3-3sigma,
MUC1, b1-integrins and delta-N p63, all of which enhance EGFR’s
ability to activate aberrant pathways that contribute to the
invasiveness of PCCs.26,33,49–52 In the present study, we also
determined that TGF-b increased EGF-mediated cell invasion and
that this effect was markedly enhanced by high levels of miR-10b.
Impressively, the combination of EGF, TGF-b and miR-10b induced
a marked increase in cancer cell invasion and EMT-like alterations
in gene expression. Thus, miR-10b was facilitating deleterious
cross-talk between EGF and TGF-b in a manner that promotes
PCC invasion. Given that miR-10b, EGFR and TGF-b are often
overexpressed in PDAC,22–26 these observations suggest that
suppressing miR-10b may prevent invasion and possibly meta-
stasis in PDAC while interrupting deleterious EGF–TGF-b inter-
actions that have the potential to contribute to PCC proliferation
in vivo.
EGF binding to EGFR activates multiple signaling pathways in
PCCs, such as the Ras/Raf/MAPK and Rac/JNK/MAPK-38,51 and EGF
then undergoes rapid endocytosis.53 The EGF/EGFR complexes
initially enter into the early endosomes where the EGFR kinase is
still active54,55 and trafﬁc to the late endosome before entering
the lysosome where EGFR undergoes degradation.56 TIP30
accelerates EGFR progression from early-to-late endosomes,
whereas TIP30 silencing causes the retention of EGF–EGFR
complexes in the early endosome thereby attenuating EGFR
degradation and prolonging its signaling.31,32,57 Inasmuch as
PDAC is associated with the overexpression of multiple members
of the EGF family, including TGF-a, heparin-binding EGF-like
growth factor, amphiregulin and betacellulin,44 our ﬁndings raise
the possibility that loss of TIP30 in PDAC may lead to EGFR
upregulation in the face of high levels of EGFR ligands that
would otherwise promote EGFR degradation. Moreover, loss of
TIP30 enhances susceptibility to tumorigenesis29 and has been
associated with metastatic breast cancer.58 Taken together, these
observations suggest that increased miR-10b in PDAC may
promote PCC proliferation and metastasis and increase disease
aggressiveness by suppressing TIP30 and upregulating EGFR. In
support of this conclusion, lower TIP30 levels were associated with
a more poorly differentiated histology, and T3M4 cells transduced
to overexpress miR-10b exhibited accelerated PCC proliferation
and intra-pancreatic tumor growth.
miR-10b promotes invasion in several cancer types by suppres-
sing the expression of various suppressors of metastasis. In breast
cancer, in addition to targeting HOXD10, miR-10b enhances
invasion by targeting syndecan-1 (SDC1), which is known to
suppress metastases.39 Moreover, miR-10b may act by suppressing
KLF4, a zinc ﬁnger transcription factor which can also suppress
metastasis formation,37,59 and NF-1,40 which attenuates ras
activity. In the present study, miR-10b did not alter HOXD10 or
TIAM-1 expression, but it decreased the expression of SDC1,
NF1 and KLF4. This selective targeting suggests that additional
factors may bind to the non-targeted mRNA moieties in PCCs,
rendering their sites inaccessible to miR-10b, as has been reported
for miR-34a.60
Figure 5. miR-10b targets in human PCCs and TIP30 expression in PDAC. (a) qRT–PCR. AsPC-1, COLO-357 and PANC-1 cells were transfected
with control (solid bars) or miR-10b precursor (open bars) for 48 h and then harvested for RNA extraction and qRT–PCR for the indicated
mRNAs. (b, c) TIP30 expression in PDAC. Immunohistochemistry for TIP30 in human PDAC tissues shows that TIP30 exhibits strong
immunoreactivity in the PCCs in well to moderately differentiated cancers (b). By contrast, the PCCs in poorly differentiated PDACs exhibit
weak TIP30 immunoreactivity (c). Insets show magnified images of boxed areas. Representative images are shown. Bars¼ 50mm. *Po0.05,
compared with respective control transfected cells.
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Gene proﬁling identiﬁed two new potential targets down-
regulated by miR-10b, RAP2A and EPHB2. Bioinformatic analysis
predicted that both genes harbor at least one miR-10b binding
site, suggesting that they are direct targets of miR-10b. RAP2A has
been implicated in cell adhesion and is induced by LKB1, whose
loss of function is associated with altered cell polarity and
enhanced metastases in lung cancer.61,62 Similarly, loss of EPHB2
has been associated with increased metastasis in colorectal and
gastric cancer.63,64 miR-10b also enhanced EGF and TGF-b-induced
expression of EMT-associated genes decreasing E-cadherin levels,
whereas increasing N-cadherin, vimentin, Twist, Snail and Zeb1
levels. Together, these ﬁndings suggest that miR-10b modulates a
repertoire of genes in PCCs whose downregulation enhances the
metastatic process while promoting EMT, which further increases
the motility and metastatic potential of these cells.
A number of reports have pointed to reciprocal modulatory
interactions between speciﬁc miRs and members of the EGF
receptor family. Thus, EGFR activation leads to increased expres-
sion of miR-21,65 miR-221 and miR-222.66 Conversely, miR-7 and
miR-133b suppress EGFR expression,67–69 whereas miR-125a and
125b suppress HER2/HER3, and miR-205 targets HER3 but not
other HERs.70,71 To our knowledge, this is the ﬁrst study showing
the potential connection between miR-10b and EGFR signaling.
Our ﬁndings also demonstrate that miR-10b facilitates poten-
tially deleterious interactions between EGFR and TGF-b pathways.
Although the exact mechanisms whereby these interactions are
enhanced by miR-10b are not known, there are several potentially
complementary possibilities. First, TGF-b receptors undergo
endocytosis and recycling, and their enhanced retention in the
early endosome can increase TGF-b receptor signaling.72 It is
therefore possible that co-retention in the early endosome may
facilitate cross-talks between these receptors. Second, both MAPK
activation and Smad signaling are essential for TGF-b-induced
EMT,73 and miR-10b enhanced EGF’s ability to activate MAPK.
Third, within the endosome, EGFR induces AGO2 phosphorylation
to AGO2-Y393, thereby reducing AGO2 binding to Dicer and
attenuating the processing of precursor miRNAs to mature
miRNAs.74,75 By contrast, TGF-b promotes Drosha-mediated
miRNA maturation76,77 and enhances the expression of
EMT-inducing miRs.35 These observations raise the possibility that
TGF-b may act, in part, by interfering with EGFR’s actions on Dicer.
In summary, our ﬁndings indicate that circulating miR-10b levels
could serve as a diagnostic biomarker in PDAC and suggest that
targeting miR-10b may represent an important therapeutic
approach in this deadly cancer that could reverse the multiple
deleterious actions of this oncomir.
Figure 6. miR-10b overexpression enhances tumor growth. (a, b) Effects of miR-10b overexpression on T3M4 growth in vivo. (a) High-
resolution ultrasound images obtained 3 weeks post-PCC injection into the pancreas show that compared with cells transduced with an
empty vector (control), miR-10b transduction dramatically enhances tumor growth. Tumors are outlined and shown are representative images
from two of five control or miR-10b-overexpressing tumors. (b) Quantitation of these tumors, calculated via three-dimensional abdominal
imaging, shows that miR-10b overexpression (open bar) significantly enhances tumor volume. Data are the means±s.e.m. for all five control
(Sham) and miR-10b-transduced tumors. A t-test was used to test for significant differences. *Po0.05. (c) Effects of miR-10b overexpression on
proliferation in vivo. Immunohistochemistry of control and miR-10b-transduced tumors shows that miR-10b overexpression enhances
proliferation as evidenced by the increased Ki67 and phospho-Histone H3 immunoreactivity when compared with control tumors. Shown are
representative H&E stains, and Ki67 and phospho-Histone H3 immunostaining from one of five control or miR-10b-transduced tumors.
Bars¼ 50mm. (d) Schematic representation of miR-10b actions in PCCs.
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MATERIALS AND METHODS
Cell culture
ASPC-1 and PANC-1 human PCCs were obtained from ATCC (Manassas, VA,
USA), which validated their authenticity. COLO-357 and T3M4 human PCCs
were a gift from Dr RS Metzger at the Duke University. Their authenticity
was validated by chromosomal analysis. ASPC-1 cells were grown in RPMI
1640, and PANC-1 and COLO-357 cells were grown in Dulbecco’s modiﬁed
Eagle’s medium. Media were supplemented with 5% fetal bovine serum,
100U/ml penicillin and 100mg/ml streptomycin (complete medium) at
37 1C in humidiﬁed 5% CO2 incubator. Serum-free medium was
supplemented with 0.1% bovine serum albumin, 5 mg/ml apotransferrin
and 5 ng/ml sodium selenite. EGF (Millipore, Billerica, MA, USA) and TGF-b
(Genentech, Inc., South San Francisco, CA, USA) were added at the
indicated concentrations.
RNA isolation and quantitation
Total RNA was extracted using TRIZOL reagent (Invitrogen, Carlsbad, CA,
USA). Assaying of mature miRNAs was performed using the TaqMan
miRNA qRT–PCR kit (Life Technologies, Gaithersburg, MD, USA) using
RNU6B as an internal control. To assay mRNAs, RNA (500 ng) was reverse
transcribed to cDNA with a high-capacity RNA-to-cDNA master mix, and
qRT–PCR was performed with Power SYBR Green Master Mix (both from
Life Technologies). Primers were designed using the Prime-BLAST online
tool.
Transfection
Cells were transfected with 20–60nM miR-10b precursor (known as pre-miR
hsa-miR-10b precursor, sense: 50-UACCCUGUAGAACCGAAUUUGUG-30 , Life
Technologies) or a control precursor (known as pre-miR non-targeting
negative control, sense: 50-UGUACUGCUUACGAUUCGGTT-30) at 50%
conﬂuency. Transfected cells were plated for MTT (3-[4,5-dimethylthiazol-
2-yl]-2,5 diphenyl tetrazolium bromide) assay (24 h post transfection) or
transwell invasion assays (48 h post transfection). Non-targeting siRNA or
siRNAs (ON-TARGETplus siRNA, Dharmacon, Lafayette, CO, USA) designed
to target TIP30 were used to silence TIP30 in COLO-357 (60 nM) and PANC-1
(20 nM) cells. For TIP30 rescue experiments, PANC-1 cells were transfected
with 20 nM miR precursor and 250 ng of pCMV-SPORT6-TIP30 cDNA and
Lipofectamine 2000 (both from Invitrogen), which was used in all
transfection studies.
Transduction
To stably overexpress miR-10b in PCCs, the MDH1-PGK-GFP microRNA-10b
retroviral construct.28 Addgene plasmid No. 16070) or an empty MDH1-
PGK-GFP construct (Addgene plasmid No. 11375) were transfected into
Phoenix cells, a 293 T-based retroviral packaging cell line (Life
Technologies). Viruses were harvested, and PCCs were transduced as
described.78 After 48 h, GFP-positive cells PCCs were isolated (Flow
Cytometry Facility, Indiana University School of Medicine, Indianapolis,
IN, USA), re-plated and cultured as described above.
MTT, invasion and migration assays
MTT assays were performed in 96-well plates.49 miR-10b precursor and
precursor control transfected cells (5 104) were plated in Matrigel pre-
coated transwell chambers (BD Biosciences, San Jose, CA, USA), and
invasion assays were performed as previously reported.49,78 UO126 (1mM)
were from Alexis Biochemicals (San Diego, CA, USA). Erlotinib (2mM;
Genentech, Inc.) and LY294002 (10mM; Calbiochem, San Diego, CA, USA)
were added to serum-free medium in the lower chamber in the absence or
presence of 1 nM EGF and/or 0.5 nM TGF-b1. Wound-healing assays were
performed as previously reported49,78 24 h after cell transfection with pre-
miR-10b oligonucleotides.
Microarray and data analysis
miR-10b precursor or control transfected PANC-1 cells were harvested at
20 h post transfection. Total RNA (three replicates per condition) was
extracted using TRIZOL reagent. Microarray analysis for microRNAs was
performed by the Genomics and Microarray Core Facility at Dartmouth
Medical School. Array data were registered with GEO (accession No.
GSE40189) for public access.
Immunoblotting
Whole-cell extracts were prepared in ice-cold lysis buffer consisting of
20mM Tris-HCl (pH 7.5), 150mM NaCl, 1mM EDTA, 1mM EGTA (ethylene
glycol tetraacetic acid), 1% Triton, 2.5mM sodium pyrophosphate, 1mM
beta-glycerophosphate, 1mM Na3VO4, 1mM PMSF and one tablet of
complete protease inhibitor/10ml. Lysates (25mg/lane) were subjected to
10-12% SDS-PAGE (sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis) and transferred to PVDF (polyvinylidene diﬂuoride; Millipore) and
immunoblotted.33 Antibodies directed against the following antigens were
used: EGFR, Phospho-EGFR Tyr1148, phospho-AKT Ser473, AKT, phospho-
p44/42 MAPK Thr202/Tyr204, p44/42 MAPK, phospho-p38 MAPK Thr180/
Tyr182, p38 MAPK (all from Cell Signaling Technology, Danvers, MA, USA),
and ERK2 (C-14, Santa Cruz Biotechnology, Santa Cruz, CA, USA). The anti-
TIP30 antibody was a kind gift from Dr Hua Xiao at the Michigan State
University.
Constructs
The LightSwitch TIP30 30UTR Reporter (Switchgear Genomics, Menlo Park,
CA, USA) was utilized to assess whether there is a direct interaction
between miR-10b and TIP30 30UTR. Site-directed mutagenesis kits
(Stratagene, La Jolla, CA, USA) were used to introduce a six-base pair
mutation in the seed-binding site of TIP30 30UTR. The pCMV-SPORT6 TIP30
cDNA construct used in the TIP30 rescue experiment was purchased from
Open Biosystems, Huntsville, AL, USA.
Luciferase reporter assay
Cells in 24-well plates (50% conﬂuency) were co-transfected with miR-10b
precursor (20 nM) and TIP30 30UTR Reporter (200 ng). Luciferase activity was
measured 24 h later using the Dual-Glo luciferase assay system (Promega,
Fitchburg, WI, USA).
Circulating miR-10b quantitation
Plasma from 20 normal, 5 chronic pancreatitis and 17 PDAC patients was
obtained from the Indiana University Simon Cancer Center Solid Tissue
Bank (Indianapolis, IN, USA). RNA was isolated from 100ml of plasma using
Trizol LS (Life Technologies, Carlsbad, CA, USA) according to the
manufacturer’s recommendations. qRT–PCR for miR-10b was performed
in duplicate with a Taqman micro RNA reverse transcription kit and a miR-
10b-speciﬁc primer/probe set (Life Technologies). Ct values were obtained
using a Viia 7 Real-time PCR System (Life Technologies). miR-10b levels
were normalized to miR-16 levels, a stable and abundant circulating
microRNA79 that is a suitable endogenous control for analyzing circulating
microRNAs in PDAC plasma.80 Fold increases were calculated relative to
miR-10b levels in normal plasma.
Orthotopic model
Sham- and miR-10b transduced T3M4 cells were injected into the tail
region of each pancreas (500.000 cells/injection) of ﬁve 8-week-old male
athymic mice. Tumors were imaged 3 weeks later with a Vevo2100 high
resolution ultrasound (Visual Sonics Inc., Toronto, ON, Canada). Tumor
volumes were calculated using the three-dimensional abdominal images
and the Vevo2100 System software. Tumors were harvested, ﬁxed,
embedded, sectioned and hematoxylin and eosin stained.81
Immunohistochemistry
Parafﬁn-embedded human PDAC tissues were obtained from the Indiana
University Simon Cancer Center Solid Tissue Bank, and 5-mm sections were
stained for TIP30 using the anti-TIP30 antibody as described.82 For the
orthotopic tumors, immunohistochemistry was performed on 5-mm
sections using Ki67 (Novocastra, UK) and phospho-Histone H3 (Cell
Signaling Technology, Inc.) antibodies.81,82
Statistical analysis
Results are presented as mean±s.e.m. Statistical differences between
groups were assessed using one sample t-test analysis, one-way or two-
way ANOVA, as indicated, followed by Bonferroni post-test analysis.
Po0.05 was considered as statistically signiﬁcant.
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